Vertex Pharmaceuticals (VRTX) EBITDA Margin (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported EBITDA Margin for 18 consecutive years, with 38.1% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA Margin rose 1536.0% year-over-year to 38.1%; the TTM figure through Mar 2026 stood at 38.31% (up 4500.0% YoY), while the FY2025 annual figure was 34.77%, up 3689.0% from the prior year.
• EBITDA Margin came in at 38.1% for Q1 2026 at Vertex Pharmaceuticals, up from 37.8% in the prior quarter.
• The five-year high for EBITDA Margin was 50.37% in Q2 2022, with the low at 132.85% in Q2 2024.
• Average EBITDA Margin over 5 years is 29.95%, with a median of 39.26% recorded in 2023.
• Across the five-year window, EBITDA Margin tumbled 17402 bps in 2024 and jumped 17168 bps in 2025, its largest moves.
• Year by year, EBITDA Margin stood at 44.88% in 2022, then fell by 13 bps to 39.26% in 2023, then fell by 10 bps to 35.23% in 2024, then grew by 7 bps to 37.8% in 2025, then advanced by 1 bps to 38.1% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 38.1%, 37.8%, and 38.56% for Q1 2026, Q4 2025, and Q3 2025 respectively.